Institute for OneWorld Health Launches Research Collaboration with Anacor Pharmaceuticals, Inc. to Develop New Treatments for Diarrheal Disease
Published: Mar 07, 2011
SOUTH SAN FRANCISCO, Calif. & PALO ALTO, Calif.--(BUSINESS WIRE)--The Institute for OneWorld Health (iOWH) and Anacor Pharmaceuticals (NASDAQ:ANAC) today announced the establishment of a joint research agreement to discover antibacterial compounds for treating shigellosis. Shigellosis, or bloody diarrhea, is an infectious disease caused by the gram-negative bacterium Shigella. An estimated 80 to 165 million people worldwide are impacted by this disease annually, which is responsible for an estimated 600,000 deaths each year, mostly among children in the poorest countries. Current therapies are losing their effectiveness due to bacterial resistance, which demands the development of new medicines to ensure effective treatment against this deadly disease.